Researchers, including those from Washington University School of Medicine in St Louis, developed the database which includes more than 14,000 drug-gene interactions involving 2,600 genes and 6,300 drugs that target those genes.
Another 6,700 genes are in the database because they potentially could be targeted with future drugs.
"We wanted to create a comprehensive database that is user-friendly, something along the lines of a Google search engine for disease genes," explained Malachi Griffith, a research instructor in genetics, who developed the database with his twin brother, Obi Griffith.
The database is weighted heavily toward cancer genes but also includes genes involved in Alzheimer's disease, heart disease, diabetes and many other illnesses.
The Griffiths created the database with a team of scientists at The Genome Institute at Washington University in St Louis.
The database is easy to search and geared toward researchers and physician-scientists who want to know whether errors in disease genes - identified through genome sequencing or other methods - potentially could be targeted with existing drug therapies.
However, researchers cautioned the database, which is publicly available and free to use, is intended for research purposes and that it does not recommend treatments.
The new database brings together information from 15 publicly available databases in the United States, Canada, Europe and Asia.
Users can enter the name of a single gene or lists of many genes to retrieve drugs targeting those genes. The search provides the names of drugs targeted to each gene and details whether the drug is an inhibitor, antibody, vaccine or another type.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
